Abstract #0370

Assessment of pancreatic tumour response on LDE225, gemcitabine and nab-paclitaxel using Intravoxel Incoherent Motion MRI

Nienke P.M. Wassenaar¹, Esther N. Pijnappel², Remy Klaassen², Femke Struik¹, Jaap Stoker¹, Jurgen H. Runge¹, Hanneke W.M. van Laarhoven², Johanna W. Wilmink², Aart J. Nederveen¹, and Oliver J. Gurney-Champion¹

¹Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

Stromal deposition can become a physical and biological barrier that prevents chemotherapy from reaching pancreatic ductal adenocarcinoma (PDAC). In this study, 34 patients were treated with LDE225, which specifically targets tumour stroma, gemcitabine and nab-paclitaxel. Pancreatic tumour response was assessed using intravoxel incoherent motion (IVIM) MRI. We found that the diffusion in PDAC increased after chemotherapy, which may be explained by reduction of stroma or tumour necrosis. Furthermore, a positive correlation was found between overall survival and the change in tumour perfusion, underlining the fact that reperfusion of PDAC by LDE225 improves prognosis.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.